13 24

Cited 0 times in

A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK)

Authors
 Min Ho Park  ;  Soo Jung Lee  ;  Woo Chul Noh  ;  Chang Wan Jeon  ;  Seok Won Lee  ;  Gil Soo Son  ;  Byung-In Moon  ;  Jin Sun Lee  ;  Sung Soo Kang  ;  Young Jin Suh  ;  Geumhee Gwak  ;  Tae Hyun Kim  ;  Young Bum Yoo  ;  Hyun-Ah Kim  ;  Min Young Kim  ;  Ju Yeon Kim  ;  Joon Jeong 
Citation
 BREAST, Vol.54 : 121-126, 2020-12 
Journal Title
 BREAST 
ISSN
 0960-9776 
Issue Date
2020-12
Keywords
Breast cancer ; Eribulin mesylate ; Korean patients ; Retrospective study
Abstract
Purpose: Approval of eribulin for metastatic breast cancer was based on data primarily from Western patients, and there is a paucity of data on the effectiveness and safety of eribulin for Asian patients. To determine the effectiveness and safety of eribulin in Korean women with breast cancer in a real-world setting, we conducted a nationwide, multicenter, retrospective study. Methods: Patients with locally advanced or metastatic breast cancer who were treated with eribulin in 14 centers throughout Korea were included in this study. Eribulin was generally administered at a dose of 1.23 mg/m2 (equivalent to 1.4 mg/m2 eribulin mesylate) by intravenous infusion for 2-5 min, or as a diluted solution, on Days 1 and 8 of every 21-day cycle. The primary endpoint was progression-free survival (PFS) rate at 6 months. Secondary endpoints included median PFS, overall survival (OS), time-to-treatment failure (TTF), tumor response rate, and incidence of hematologic treatment-emergent adverse events (TEAEs). Results: The safety and full analysis populations included 398 and 360 (38 had no efficacy data) patients, respectively. The PFS rate at 6 months was 37.8%. Median PFS, OS, and TTF were 134, 631, and 120 days, respectively. Objective response rate, clinical benefit rate, and disease control rate were 18.1%, 50.6%, and 49.4%, respectively. Hematologic TEAEs were reported in 65.1% of patients; neutropenia (56.8%) and anemia (11.3%) were most common. Conclusion: Real-world effectiveness and safety of eribulin in Korean breast cancer patients were consistent with previous reports; no new safety concerns were identified.
Files in This Item:
T202005722.pdf Download
DOI
10.1016/j.breast.2020.09.004
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Jeong, Joon(정준) ORCID logo https://orcid.org/0000-0003-0397-0005
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/181441
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links